EPRX
OtherEupraxia Pharmaceuticals Inc. Common Stock
Live · XNAS · May 9, Close
What's Moving EPRX Today?
No stock-specific AI insight has been generated for EPRX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
EPRX News
21 articles- Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease WeekYahoo Finance·May 6, 2026
- Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)Yahoo Finance·May 5, 2026
- Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical OfficerYahoo Finance·May 1, 2026
- Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual MeetingYahoo Finance·Apr 22, 2026
- Eupraxia Reports Latest 36-Week Results From Resolve TrialYahoo Finance·Apr 21, 2026
- Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic EsophagitisYahoo Finance·Apr 21, 2026
- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsightGlobeNewswire Inc.·Apr 13, 2026
- Eupraxia Pharmaceuticals to Present at Upcoming Investor ConferencesYahoo Finance·Apr 13, 2026
- New Strong Sell Stocks for April 2ndYahoo Finance·Apr 2, 2026
- Eupraxia Reports Positive Six-Month Data From Eosinophilic Esophagitis TrialYahoo Finance·Mar 17, 2026
- Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic EsophagitisYahoo Finance·Mar 17, 2026
- Eupraxia Pharmaceuticals Q4 Loss WidensYahoo Finance·Mar 13, 2026
- Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial ResultsYahoo Finance·Mar 13, 2026
- Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter OptionYahoo Finance·Feb 20, 2026
- Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter OptionYahoo Finance·Feb 20, 2026
- Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public OfferingYahoo Finance·Feb 19, 2026
- Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded WarrantsYahoo Finance·Feb 19, 2026
- Eupraxia Pharmaceuticals Announces Proposed Public OfferingYahoo Finance·Feb 18, 2026
- Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn SituationYahoo Finance·Feb 5, 2026
- Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve TrialYahoo Finance·Jan 8, 2026
- Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on BiopsyYahoo Finance·Jan 8, 2026
All 21 articles loaded
Price Data
Fundamentals
Trading
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.